These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15852036)

  • 1. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.
    Douglas SA; Behm DJ; Aiyar NV; Naselsky D; Disa J; Brooks DP; Ohlstein EH; Gleason JG; Sarau HM; Foley JJ; Buckley PT; Schmidt DB; Wixted WE; Widdowson K; Riley G; Jin J; Gallagher TF; Schmidt SJ; Ridgers L; Christmann LT; Keenan RM; Knight SD; Dhanak D
    Br J Pharmacol; 2005 Jul; 145(5):620-35. PubMed ID: 15852036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
    Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
    Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.
    Douglas SA; Naselsky D; Ao Z; Disa J; Herold CL; Lynch F; Aiyar NV
    Br J Pharmacol; 2004 Jul; 142(6):921-32. PubMed ID: 15210573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.
    Behm DJ; Herold CL; Ohlstein EH; Knight SD; Dhanak D; Douglas SA
    Br J Pharmacol; 2002 Oct; 137(4):449-58. PubMed ID: 12359626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.
    Behm DJ; Herold CL; Camarda V; Aiyar NV; Douglas SA
    Eur J Pharmacol; 2004 May; 492(2-3):113-6. PubMed ID: 15178353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning and pharmacological characterization of the cat urotensin-II receptor (UT).
    Aiyar N; Johns DG; Ao Z; Disa J; Behm DJ; Foley JJ; Buckley PT; Sarau HM; van-der-Keyl HK; Elshourbagy NA; Douglas SA
    Biochem Pharmacol; 2005 Apr; 69(7):1069-79. PubMed ID: 15763543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
    Behm DJ; Harrison SM; Ao Z; Maniscalco K; Pickering SJ; Grau EV; Woods TN; Coatney RW; Doe CP; Willette RN; Johns DG; Douglas SA
    Br J Pharmacol; 2003 May; 139(2):464-72. PubMed ID: 12770952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle.
    Behm DJ; Ao Z; Camarda V; Aiyar NV; Johns DG; Douglas SA
    Eur J Pharmacol; 2005 Jun; 516(3):276-81. PubMed ID: 15975570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.
    Elshourbagy NA; Douglas SA; Shabon U; Harrison S; Duddy G; Sechler JL; Ao Z; Maleeff BE; Naselsky D; Disa J; Aiyar NV
    Br J Pharmacol; 2002 May; 136(1):9-22. PubMed ID: 11976263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.
    Behm DJ; Aiyar NV; Olzinski AR; McAtee JJ; Hilfiker MA; Dodson JW; Dowdell SE; Wang GZ; Goodman KB; Sehon CA; Harpel MR; Willette RN; Neeb MJ; Leach CA; Douglas SA
    Br J Pharmacol; 2010 Sep; 161(1):207-28. PubMed ID: 20718751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.
    Herold CL; Behm DJ; Buckley PT; Foley JJ; Wixted WE; Sarau HM; Douglas SA
    Br J Pharmacol; 2003 May; 139(2):203-7. PubMed ID: 12770925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.
    Behm DJ; McAtee JJ; Dodson JW; Neeb MJ; Fries HE; Evans CA; Hernandez RR; Hoffman KD; Harrison SM; Lai JM; Wu C; Aiyar NV; Ohlstein EH; Douglas SA
    Br J Pharmacol; 2008 Oct; 155(3):374-86. PubMed ID: 18587423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new ligand for the urotensin II receptor.
    Camarda V; Guerrini R; Kostenis E; Rizzi A; Calò G; Hattenberger A; Zucchini M; Salvadori S; Regoli D
    Br J Pharmacol; 2002 Oct; 137(3):311-4. PubMed ID: 12237249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
    Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
    J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor.
    Langmead CJ; Jerman JC; Brough SJ; Scott C; Porter RA; Herdon HJ
    Br J Pharmacol; 2004 Jan; 141(2):340-6. PubMed ID: 14691055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.
    Patacchini R; Santicioli P; Giuliani S; Grieco P; Novellino E; Rovero P; Maggi CA
    Br J Pharmacol; 2003 Dec; 140(7):1155-8. PubMed ID: 14645137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation.
    Behm DJ; Ogbonna A; Wu C; Burns-Kurtis CL; Douglas SA
    J Pharmacol Exp Ther; 2009 Jan; 328(1):231-9. PubMed ID: 18836067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
    Gunthorpe MJ; Hannan SL; Smart D; Jerman JC; Arpino S; Smith GD; Brough S; Wright J; Egerton J; Lappin SC; Holland VA; Winborn K; Thompson M; Rami HK; Randall A; Davis JB
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of filtration-based time-resolved fluorescence assay for the high-throughput screening of urotensin II receptor antagonist.
    Oh KS; Lee S; Lee BH
    Assay Drug Dev Technol; 2011 Oct; 9(5):514-21. PubMed ID: 21561377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
    Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
    J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.